66 related articles for article (PubMed ID: 6502959)
1. [Thrombus formation with special reference to the substrates, fibrinogen and its related substances].
Matsuda M
Rinsho Ketsueki; 1984 Jul; 25(7):984-91. PubMed ID: 6502959
[No Abstract] [Full Text] [Related]
2. [Contact (prekallikrein) and fibrinolytic (plasminogen/antiplasmin value) system in the physiopathology of vascular complications of diabetes].
Janody D; Droulle C; Adjizian JC; Ostermann G; Poynard JP; Jeunehomme G; Leutenegger M; Potron G
J Mal Vasc; 1982; 7(3):221-4. PubMed ID: 6815291
[TBL] [Abstract][Full Text] [Related]
3. [Relevance of fibrinogen/fibrin degradation products in the study of thrombosis].
Páramo JA; Gaffney PJ
Sangre (Barc); 1989 Dec; 34(6):497-501. PubMed ID: 2697948
[No Abstract] [Full Text] [Related]
4. Plasmin generation plays different roles in the formation and removal of arterial and venous thrombus in mice.
Matsuno H; Kozawa O; Okada K; Ueshima S; Matsuo O; Uematsu T
Thromb Haemost; 2002 Jan; 87(1):98-104. PubMed ID: 11848464
[TBL] [Abstract][Full Text] [Related]
5. [Effect of matrix composition on chemotaxis response of monocytes stimulated by monocyte chemoattractant protein-1].
Kukhtina NB; Aref'eva TI; Aref'eva AM; Krasnikova TL
Ross Fiziol Zh Im I M Sechenova; 2003 Dec; 89(12):1577-81. PubMed ID: 14870496
[TBL] [Abstract][Full Text] [Related]
6. High plasma fibrinogen level is associated with poor clinical outcome in DIC patients.
Wada H; Mori Y; Okabayashi K; Gabazza EC; Kushiya F; Watanabe M; Nishikawa M; Shiku H; Nobori T
Am J Hematol; 2003 Jan; 72(1):1-7. PubMed ID: 12508260
[TBL] [Abstract][Full Text] [Related]
7. Intravascular and peritoneal coagulation and fibrinolysis in horses with acute gastrointestinal tract diseases.
Collatos C; Barton MH; Prasse KW; Moore JN
J Am Vet Med Assoc; 1995 Aug; 207(4):465-70. PubMed ID: 7591947
[TBL] [Abstract][Full Text] [Related]
8. Biological properties of fibrinogen derivatives relevant to the function of cardiovascular system and immuno-inflammatory reaction.
Kopec M
New Istanbul Contrib Clin Sci; 1977 Sep; 12(1):43-9. PubMed ID: 565049
[No Abstract] [Full Text] [Related]
9. Like fibrin, (DD)E, the major degradation product of crosslinked fibrin, protects plasmin from inhibition by alpha2-antiplasmin.
Lee AY; Fredenburgh JC; Stewart RJ; Rischke JA; Weitz JI
Thromb Haemost; 2001 Mar; 85(3):502-8. PubMed ID: 11307822
[TBL] [Abstract][Full Text] [Related]
10. Fibrinogen fragment D is necessary and sufficient to anchor a surface plasminogen-activating complex in Streptococcus pyogenes.
Hess JL; Boyle MD
Proteomics; 2006 Jan; 6(1):375-8. PubMed ID: 16287173
[TBL] [Abstract][Full Text] [Related]
11. Effects of fibrin and alpha2-antiplasmin on plasminogen activation by staphylokinase.
Okada K; Ueshima S; Takaishi T; Yuasa H; Fukao H; Matsuo O
Am J Hematol; 1996 Nov; 53(3):151-7. PubMed ID: 8895684
[TBL] [Abstract][Full Text] [Related]
12. Outcome of treatment of deep-vein thrombosis with urokinase: relationship to dosage, duration of therapy, age of the thrombus and laboratory changes.
D'Angelo A; Mannucci PM
Thromb Haemost; 1984 Apr; 51(2):236-9. PubMed ID: 6740556
[TBL] [Abstract][Full Text] [Related]
13. Fluorogenic fibrinogen and fibrin facilitate macromolecular assembly and dynamic assay of picomolar levels of plasminogen activators under well mixed conditions.
Wu JH; Diamond SL
Thromb Haemost; 1995 Aug; 74(2):711-7. PubMed ID: 8585011
[TBL] [Abstract][Full Text] [Related]
14. The ability of fibrinogens, FI and FII, to support ADP-induced platelet aggregation.
Phillips HM; Mansouri A; Perry CA
Thromb Haemost; 1983 Aug; 50(2):527-9. PubMed ID: 6636032
[TBL] [Abstract][Full Text] [Related]
15. Relationships among tumor burden, tumor size, and the changing concentrations of fibrin degradation products and fibrinolytic factors in the pleural effusions of rabbits with VX2 lung tumors.
Hatton MW; Southward SM; Ross BL; Clarke BJ; Singh G; Richardson M
J Lab Clin Med; 2006 Jan; 147(1):27-35. PubMed ID: 16443002
[TBL] [Abstract][Full Text] [Related]
16. The stimulatory capacity of soluble fibrin prepared from high and low molecular weight fibrinogen on plasminogen activation.
Halvorsen S; Skjønsberg OH; Godal HC
Blood Coagul Fibrinolysis; 1993 Feb; 4(1):133-7. PubMed ID: 8457641
[TBL] [Abstract][Full Text] [Related]
17. The use of soluble fibrin in evaluating the acute and chronic hypercoagulable state.
Dempfle CE
Thromb Haemost; 1999 Aug; 82(2):673-83. PubMed ID: 10605767
[TBL] [Abstract][Full Text] [Related]
18. Dysbaric osteonecrosis: a consequence of intravascular bubble formation, endothelial damage, and platelet thrombosis.
Slichter SJ; Stegall P; Smith K; Huang TW; Harker LA
J Lab Clin Med; 1981 Oct; 98(4):568-90. PubMed ID: 7288270
[TBL] [Abstract][Full Text] [Related]
19. [Intensification of the effect of exogenous plasminogen activators on lysis of fibrin blood clots due to a decrease in the level of alpha-2- antiplasmin by a plasmasorption method].
Ogloblina OG; Saburova OS; Semenova OA; Belova LA
Biokhimiia; 1994 Jan; 59(1):62-8. PubMed ID: 7509643
[TBL] [Abstract][Full Text] [Related]
20. [A novel molecular marker for thrombus formation and life prognosis--clinical usefulness of measurement of soluble fibrin monomer-fibrinogen complex (SF)].
Koga S
Rinsho Byori; 2004 Apr; 52(4):355-61. PubMed ID: 15164605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
